Expanded Access to Upadacitinib

AbbVie

Status

Conditions: Atopic Dermatitis; Idiopathic Arthritis (Including sJIA, pJIA, or JPsA); Ulcerative Colitis; Crohn Disease

Treatments: Drug: Upadacitinib

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT04159597

C25-267 (Other Identifier)

C20-082

Details and patient eligibility

About

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to upadacitinib prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Sex: All

Ages: 2 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria:

• There are other suitable treatment options.
• The participant qualifies for ongoing clinical trials.